Globus Medical stock soars to all-time high of $91.59

Globus Medical Inc. (NYSE:GMED) shares have reached an unprecedented peak, touching an all-time high of $91.59. According to InvestingPro analysis, the company's current market capitalization stands at $12.36 billion, with the stock currently trading above its Fair Value. This milestone underscores a period of robust performance for the medical device company, which has seen its stock value surge by an impressive 62.06% over the past year. The company's financial health appears strong, with a healthy current ratio of 2.51 and remarkable revenue growth of 102.1% in the last twelve months. Investors have shown increasing confidence in Globus Medical 's growth trajectory and market position, as the company continues to innovate in the musculoskeletal solutions space. The all-time high represents not just a 52-week triumph but also sets a new benchmark in the company's financial history, reflecting a strong investor endorsement of its strategic direction and future potential. For deeper insights into GMED's valuation and 17 additional ProTips, including detailed analysis of its market position, visit InvestingPro.

In other recent news, Globus Medical has reported significant growth in recent developments. The company announced preliminary results for Q4 2024, surpassing both Canaccord Genuity's and Street estimates. The new revenue guidance suggests a 6.2% growth, leading Canaccord Genuity to increase its price target to $101 from the previous $92. Truist Securities maintained its Hold rating on Globus Medical, following the company's Q4 sales figure that exceeded consensus estimates by 3.5%, reaching $657 million.

Globus Medical's successful merger with NuVasive (NASDAQ:NUVA) led to a 6.6% rise in Q4 2024 sales and a 60.6% surge in full-year sales for 2024. The company has issued guidance for 2025, projecting revenues between $2.66 billion and $2.69 billion and earnings per share in the range of $3.40 to $3.50.

BofA Securities upgraded shares of Globus Medical from Underperform to Neutral and increased the price target to $97 from $80, following the successful integration of NuVasive. Analysts from Roth/MKM and BTIG have maintained a Buy rating on Globus Medical's stock, citing potential growth from merger-related synergies and the expansion of robotics.

RBC Capital Markets projected a positive outlook for the Medical (TASE:PMCN) Supplies & Devices sector for 2025, highlighting stocks like Boston Scientific (NYSE:BSX) and Intuitive Surgical (NASDAQ:ISRG). Their smid-cap selections feature Globus Medical, Penumbra (NYSE:PEN), and Insulet (NASDAQ:PODD) Corporation. These recent developments highlight Globus Medical's strong performance and growth potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.